116 reports of this reaction
0.8% of all LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN reports
#16 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #16 most commonly reported adverse reaction for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, manufactured by Novartis Pharmaceuticals Corporation. There are 116 FDA adverse event reports linking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN to HAEMOGLOBIN DECREASED. This represents approximately 0.8% of all 14,999 adverse event reports for this drug.
Patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is a less commonly reported adverse event for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, but still significant enough to appear in the safety profile.
In addition to haemoglobin decreased, the following adverse reactions have been reported for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 116 FDA reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 0.8% of all adverse event reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, making it a notable side effect.
If you experience haemoglobin decreased while taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.